Selected Publications Ariel Dora Stern
Michael S. Sinha, Ariel D. Stern, and Arti K. Rai. “ Four Decades of Orphan Drugs and Priorities for the Future” New England Journal of Medicine 391;2 (July 2024).
Miller, Kathleen L., Ariel D. Stern, Aaron Kearsley, and Jennifer Kao. "FDA Breakthrough Therapy Designation Reduced Late-Stage Drug Development Time" Health Affairs 43, no. 7 (2024): 1003-1010.
Amitabh Chandra, Jennifer Kao, Kathleen L. Miller, Ariel D. Stern; Regulatory Incentives for Innovation: The FDA's Breakthrough Therapy Designation. The Review of Economics and Statistics 2024; doi: https://doi.org/10.1162/rest_a_01434
Masanneck, Lars, and Ariel D. Stern. "Tracing Digital Therapeutics Research Across Medical Specialties: Evidence from ClinicalTrials. gov." Clinical Pharmacology & Therapeutics (2024).
Tang, Mitchell, Rebecca G. Mishuris, Lily Payvandi, and Ariel D. Stern. "Differences in Care Team Response to Patient Portal Messages by Patient Race and Ethnicity." JAMA Network Open 7, no. 3 (2024): e242618-e242618.
Aboy, Mateo, Cristina Crespo, and Ariel D. Stern. “Beyond the 510(k): The regulation of novel moderate-risk medical devices, intellectual property considerations, and innovation incentives in the FDA’s De Novo pathway.” npj Digital Medicine 7, 29 (2024). doi.org/10.1038/s41746-024-01021-y
Marra, Caroline, and Ariel D. Stern. "Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms." Clinical Pharmacology & Therapeutics (2024).
Brönneke, Jan Benedikt, Annika Herr, Simon Reif, and Ariel D. Stern. “Dynamic HTA for Digital Health Solutions: Opportunities and Challenges for Patient-Centered Evaluation.” International Journal of Technology Assessment in Health Care (2023).
Tang, Mitchell, Carter H. Nakamoto, Ariel D. Stern, Jose R. Zubizarreta, Felippe O. Marcondes, Lori Uscher-Pines, Lee H. Schwamm, and Ateev Mehrotra. "Effects of Remote Patient Monitoring Use on Care Outcomes Among Medicare Patients with Hypertension." Annals of Internal Medicine (2023).
Tang, Mitchell, Ateev Mehrotra, and Ariel D. Stern. “Rapid Growth of Remote Patient Monitoring Is Driven By A Small Number Of Primary Care Providers” Health Affairs 41:9, 1248-1254 (2022)
Torous, John, Ariel D. Stern, and Florence Bourgeois. “Regulatory Considerations to Keep Pace with Innovation in Digital Health Products.” npj Digital Medicine 5, 12 (2022). https://doi.org/10.1038/s41746-022-00668-9
Tang Mitchell, Carter H. Nakamoto, Ariel D. Stern, Ateev Mehrotra. Trends in Remote Patient Monitoring Use in Traditional Medicare. JAMA Internal Medicine. Published online August 01, 2022. doi:10.1001/jamainternmed.2022.3043
Stern, Ariel D., et al. “Advancing digital health applications: Priorities for innovation in real-world evidence generation.” The Lancet Digital Health 4(3) doi: doi.org/10.1016/S2589-7500(21)00292-2 (March 2022)
Mecklai, Keizra, Nicholas Smith, Ariel D. Stern, and Daniel B.Kramer. “Remote Patient Monitoring – Overdue or Overused?” New England Journal of Medicine 384:1384-1386 (April 2021).
Gordon, William J., Andrea R. Coravos, and Ariel D. Stern “Ushering in safe, effective, secure, and ethical medicine in the digital era” npj Digital Medicine 4(56) (March 2021).
Lauenroth, Victoria, Aaron S. Kesselheim, Ameet Sarpatwari, and Ariel D. Stern “Lessons from the impact of price regulation on the pricing of anticancer drugs in Germany” Health Affairs, 39(7) (July 2020) [1185-1193].
Marra, Caroline, Jacqueline Chen, Andrea R. Corovos, and Ariel D. Stern “Quantifying the Use of Connected Digital Products in Clinical Research.” npj Digital Medicine 3(50) (April 2020).
Lite, Samuel S., William J. Gordon, and Ariel D. Stern. “Association of the Meaningful Use Electronic Health Record Incentive Program with Health Information Technology Venture Capital Funding.” JAMA Network Open (March 2020).
Stern, Ariel D. “Managing the use and dissemination of information about biomarkers: The importance of incentive structures.” The Journal of Law, Medicine & Ethics, 47(3) (September 2019) [396-397].
Angus, Derek C., Brian M. Alexander, Ariel D. Stern, et al. “Adaptive Platform Trials: Definition, Design, Conduct, and Reporting Considerations.” Nature Reviews Drug Discovery (August 2019).
Gordon, William J. and Ariel D. Stern “Challenges and Opportunities in Software-Driven Medical Devices.” Nature: Biomedical Engineering, 3(7) (July 2019) [493-497].
Stern, Ariel D., Felicitas Pietrulla, Annika Herr, Aaron S. Kesselheim, and Ameet Sarpatwari. “The Impact of Price Regulation on the Availability of New Drugs in Germany.” Health Affairs, 38(7) (July 2019) [1182-1187].
Stern, Ariel D., William J. Gordon, Adam B. Landman, and Daniel B. Kramer. “Cybersecurity Features of Digital Medical Devices: An Analysis of FDA Product Summaries.” BMJ Open doi: 10.1136/bmjopen-2018-025374 (June 2019).
Cutler, David, Jonathan S. Skinner, Ariel D. Stern, and David Wennberg. “Physician Beliefs and Patient Preferences: A New Look at Regional Variation in Health Care Spending.” American Economic Journal: Economic Policy, 11(1) (February 2019) [192–221]. Finalist, National Institute for Health Care Management Foundation Annual Health Care Research Award (2020)
Stern, Ariel D., Brian M. Alexander, and Amitabh Chandra. “Innovation Incentives and Biomarkers.” Clinical Pharmacology and Therapeutics, 103(1) (January 2018) [34-36].
Kaplan, Aaron V. and Ariel D. Stern. “The Central and Unacknowledged Role of the U.S. Food and Drug Administration in the Design and Execution of Medical Device Pivotal Trials.” JAMA Cardiology, 3(1) (January 2018) [5-6].
Stern, Ariel D., Brian M. Alexander, and Amitabh Chandra. “How Economics Can Shape Precision Medicines.” Science, 355 (6330) (March 2017) [1131-1133].
Stern, Ariel D. “Innovation Under Regulatory Uncertainty: Evidence from Medical Technology.” Journal of Public Economics, 145 (January 2017) [181-200].
Stern, Ariel D. Handelsblatt Op-Ed “Warum wir gerade an einem Wendepunkt im Gesundheitswesen stehen.“ June 2024.
Stern, Ariel D. The Cold Call Podcast with Brian Kenney “Can Remote Surgeries Digitally Transform Operating Rooms?” September 2023.
Grimpe, Christoph, Timo Minssen, W. Nicholson Price II, and Ariel D. Stern, “Ein Booster für die Pharmabranche” Harvard Business Manager (Germany) Print Edition, July 2022.
Grimpe, Christoph, Timo Minssen, W. Nicholson Price II, and Ariel D. Stern, “Will mRNA Technology Companies Spawn Innovation Ecosystems?” Harvard Business Review Digital Article, April 2022.